The answer is more complicated than you might hope
Reversibility: Data from the CTR-1011 trial showed that when patients were switched from Tesamorelin to a placebo, the visceral fat typically returned to baseline levels within several months
Of these, MALA is the rare and most severe form, with a mortality rate of up to 50%
Reimbursement data shows a marked increase in spending in Q3 and Q4 , likely due to more aggressive prescribing for weight loss: Q1 2024: ~$65M Q2 2024: ~$70M Q3 2024: ~$170M Q4 2024: ~$190M Unlike Ozempic, Wegovy reimbursements were more evenly distributed across dosage levels , from 0.25mg up to the full 2.4mg dose
Still, many doctors prescribe them off-label to help patients manage their weight because the active ingredient is the same as in Wegovy and Zepbound, just at a different dose
Song G, Han H, Park S, et